Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
09 2021
Historique:
received: 15 09 2020
accepted: 15 04 2021
revised: 08 04 2021
pubmed: 7 5 2021
medline: 22 3 2022
entrez: 6 5 2021
Statut: ppublish

Résumé

The biological function of PRMT5 remains poorly understood in cervical cancer metastasis. Here, we report that PRMT5 physically associates with the transcription factor Snail and the NuRD(MTA1) complex to form a transcriptional-repressive complex that catalyzes the symmetrical histone dimethylation and deacetylation. This study shows that the Snail/PRMT5/NuRD(MTA1) complex targets genes, such as TET1 and E-cadherin, which are critical for epithelial-mesenchymal transition (EMT). This complex also affects the conversion of 5mC to 5hmC. This study demonstrates that the Snail/PRMT5/NuRD(MTA1) complex promotes the invasion and metastasis of cervical cancer in vitro and in vivo. This study also shows that PRMT5 expression is upregulated in cervical cancer and various human cancers, and the PRMT5 inhibitor EPZ015666 suppresses EMT and the invasion potential of cervical cancer cells by disinhibiting the expression of TET1 and increasing 5hmC, suggesting that PRMT5 is a potential target for cancer therapy.

Identifiants

pubmed: 33953349
doi: 10.1038/s41418-021-00786-z
pii: 10.1038/s41418-021-00786-z
pmc: PMC8408166
doi:

Substances chimiques

Proto-Oncogene Proteins 0
Snail Family Transcription Factors 0
Mixed Function Oxygenases EC 1.-
TET1 protein, human EC 1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2818-2836

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81902882
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81802816
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81773017
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 41931291
Organisme : Chinese Ministry of Science and Technology | Department of S and T for Social Development (Department of S&T for Social Development)
ID : 2016YFA0102400

Informations de copyright

© 2021. The Author(s).

Références

Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochemical Sci. 2011;36:633–41.
doi: 10.1016/j.tibs.2011.09.001
Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, Sif S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 2007;26:3558–69.
pubmed: 17627275 pmcid: 1949000 doi: 10.1038/sj.emboj.7601794
Dhar SS, Lee SH, Kan PY, Voigt P, Ma L, Shi X, et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev. 2012;26:2749–62.
pubmed: 23249737 pmcid: 3533079 doi: 10.1101/gad.203356.112
Tsai WW, Niessen S, Goebel N, Yates JR 3rd, Guccione E, Montminy M. PRMT5 modulates the metabolic response to fasting signals. Proc Natl Acad Sci USA. 2013;110:8870–5.
pubmed: 23671120 pmcid: 3670393 doi: 10.1073/pnas.1304602110
Krause CD, Yang ZH, Kim YS, Lee JH, Cook JR, Pestka S. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Therapeutics. 2007;113:50–87.
doi: 10.1016/j.pharmthera.2006.06.007
Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z, Gheyi T, et al. Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci USA. 2012;109:17960–5.
pubmed: 23071334 pmcid: 3497828 doi: 10.1073/pnas.1209814109
Burgos ES, Wilczek C, Onikubo T, Bonanno JB, Jansong J, Reimer U, et al. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase. J Biol Chem. 2015;290:9674–89.
pubmed: 25713080 pmcid: 4392268 doi: 10.1074/jbc.M115.636894
Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000;14:3102–14.
pubmed: 11124803 pmcid: 317128 doi: 10.1101/gad.854900
Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18:329–40.
pubmed: 20951943 pmcid: 2957477 doi: 10.1016/j.ccr.2010.08.012
Wang L, Pal S, Sif S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol. 2008;28:6262–77.
pubmed: 18694959 pmcid: 2577430 doi: 10.1128/MCB.00923-08
Hu D, Gur M, Zhou Z, Gamper A, Hung MC, Fujita N, et al. Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. Nat Commun. 2015;6:8419.
pubmed: 26420673 doi: 10.1038/ncomms9419
Scoumanne A, Zhang J, Chen X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 2009;37:4965–76.
pubmed: 19528079 pmcid: 2731901 doi: 10.1093/nar/gkp516
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
doi: 10.1016/j.cell.2011.02.013 pubmed: 21376230
Liu R, Gao J, Yang Y, Qiu R, Zheng Y, Huang W, et al. PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumorigenesis. Nucleic Acids Res. 2018;46:6608–26.
pubmed: 29846670 pmcid: 6061854 doi: 10.1093/nar/gky461
Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004;24:9630–45.
pubmed: 15485929 pmcid: 522266 doi: 10.1128/MCB.24.21.9630-9645.2004
Chie L, Cook JR, Chung D, Hoffmann R, Yang Z, Kim Y, et al. A protein methyl transferase, PRMT5, selectively blocks oncogenic ras-p21 mitogenic signal transduction. Ann Clin Lab Sci. 2003;33:200–7.
pubmed: 12817625
Li X, Wang C, Jiang H, Luo C. A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019;29:97–114.
pubmed: 30640571 doi: 10.1080/13543776.2019.1567711
Radzisheuskaya A, Shliaha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat Struct Mol Biol. 2019;26:999–1012.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.
pubmed: 12189386 doi: 10.1038/nrc822
Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13:963–72.
pubmed: 24168186 pmcid: 4004763 doi: 10.2174/15680096113136660102
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
pubmed: 24556840 pmcid: 4240281 doi: 10.1038/nrm3758
Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012;31:583–94.
pubmed: 21685935 doi: 10.1038/onc.2011.254
Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene. 2013;32:1351–62.
pubmed: 22562246 doi: 10.1038/onc.2012.169
Lin T, Ponn A, Hu X, Law BK, Lu J. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene. 2010;29:4896–904.
pubmed: 20562920 pmcid: 3093107 doi: 10.1038/onc.2010.234
Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 2004;24:306–19.
pubmed: 14673164 pmcid: 303344 doi: 10.1128/MCB.24.1.306-319.2004
Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998;395:917–21.
pubmed: 9804427 doi: 10.1038/27699
Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433–8.
pubmed: 17694084 doi: 10.1038/sj.onc.1210611
Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009;138:660–72.
pubmed: 19703393 doi: 10.1016/j.cell.2009.05.050
Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L, et al. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell. 2015;27:822–36.
pubmed: 26028330 doi: 10.1016/j.ccell.2015.04.011
Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E, et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006;26:843–51.
pubmed: 16428440 pmcid: 1347035 doi: 10.1128/MCB.26.3.843-851.2006
Sen N, Gui B, Kumar R. Physiological functions of MTA family of proteins. Cancer Metastasis Rev. 2014;33:869–77.
pubmed: 25344801 pmcid: 4245464 doi: 10.1007/s10555-014-9514-4
Kumar R, Wang RA. Structure, expression and functions of MTA genes. Gene. 2016;582:112–21.
pubmed: 26869315 pmcid: 4785049 doi: 10.1016/j.gene.2016.02.012
Yao YL, Yang WM. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem. 2003;278:42560–8.
pubmed: 12920132 doi: 10.1074/jbc.M302955200
Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113:207–19.
pubmed: 12705869 doi: 10.1016/S0092-8674(03)00234-4
Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12:1479–86.
pubmed: 16533771 doi: 10.1158/1078-0432.CCR-05-1519
Malisetty VL, Penugurti V, Panta P, Chitta SK, Manavathi B. MTA1 expression in human cancers—-clinical and pharmacological significance. Biomed Pharmacother. 2017;95:956–64.
pubmed: 28915537 doi: 10.1016/j.biopha.2017.09.025
Gao J, Yang Y, Qiu R, Zhang K, Teng X, Liu R, et al. Proteomic analysis of the OGT interactome: novel links to epithelial-mesenchymal transition and metastasis of cervical cancer. Carcinogenesis. 2018;39:1222–34.
Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS. Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition? Semin Cancer Biol. 2014;27:39–45.
pubmed: 24954011 pmcid: 4165636 doi: 10.1016/j.semcancer.2014.06.003
Li DQ, Pakala SB, Nair SS, Eswaran J, Kumar R. Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res. 2012;72:387–94.
pubmed: 22253283 pmcid: 3261506 doi: 10.1158/0008-5472.CAN-11-2345
Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:432–7.
pubmed: 25915199 doi: 10.1038/nchembio.1810
Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28:4772–81.
pubmed: 18519590 pmcid: 2493371 doi: 10.1128/MCB.00323-08
Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 2010;29:1803–16.
pubmed: 20389281 pmcid: 2885925 doi: 10.1038/emboj.2010.63
Hou Z, Peng H, Ayyanathan K, Yan KP, Langer EM, Longmore GD, et al. The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol Cell Biol. 2008;28:3198–207.
pubmed: 18347060 pmcid: 2423142 doi: 10.1128/MCB.01435-07
Zheng Y, Zeng Y, Qiu R, Liu R, Huang W, Hou Y, et al. The homeotic protein SIX3 suppresses carcinogenesis and metastasis through recruiting the LSD1/NuRD(MTA3) complex. Theranostics. 2018;8:972–89.
pubmed: 29463994 pmcid: 5817105 doi: 10.7150/thno.22328
Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 1998;95:279–89.
pubmed: 9790534 doi: 10.1016/S0092-8674(00)81758-4
Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128–34.
pubmed: 29326430 doi: 10.1038/nrc.2017.118
Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases. Epigenomics. 2015;7:247–65.
pubmed: 25942534 doi: 10.2217/epi.14.80
Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 2013;110:9920–5.
pubmed: 23716660 pmcid: 3683728 doi: 10.1073/pnas.1305172110
Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733–50.
pubmed: 27036965 pmcid: 4826392 doi: 10.1101/gad.276568.115
Zhou Z, Zhang HS, Liu Y, Zhang ZG, Du GY, Li H, et al. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin. J Cell Physiol. 2018;233:1359–69.
pubmed: 28513825 doi: 10.1002/jcp.26012
Su PH, Hsu YW, Huang RL, Chen LY, Chao TK, Liao CC, et al. TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. Cancer Lett. 2019;450:53–62.
pubmed: 30771438 doi: 10.1016/j.canlet.2019.01.033
Wu J, Li H, Shi M, Zhu Y, Ma Y, Zhong Y, et al. TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/beta-catenin signaling pathway to suppress EMT in pancreatic tumor cells. J Exp Clin Cancer Res. 2019;38:348.
pubmed: 31399111 pmcid: 6688318 doi: 10.1186/s13046-019-1334-5
Chrysanthou S, Senner CE, Woods L, Fineberg E, Okkenhaug H, Burge S, et al. A critical role of TET1/2 proteins in cell-cycle progression of trophoblast stem cells. Stem Cell Rep. 2018;10:1355–68.
doi: 10.1016/j.stemcr.2018.02.014
Dong Z, Li S, Wu X, Niu Y, Liang X, Yang L, et al. Aberrant hypermethylation-mediated downregulation of antisense lncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression and prognosis of esophageal squamous cell carcinoma. Cell Death Dis. 2019;10:930.
pubmed: 31804468 pmcid: 6895126 doi: 10.1038/s41419-019-2171-3
Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13:37–50.
pubmed: 23235912 doi: 10.1038/nrc3409
Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011;71:5579–87.
pubmed: 21700716 pmcid: 3156344 doi: 10.1158/0008-5472.CAN-11-0458
Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013;61:206–17.
pubmed: 23292799 pmcid: 3636695 doi: 10.1369/0022155413475452
Uzdensky A, Demyanenko S, Bibov M, Sharifulina S, Kit O, Przhedetski Y, et al. Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin. Tumour Biol. 2014;35:8225–33.
pubmed: 24850177 doi: 10.1007/s13277-014-2098-3
Tee WW, Pardo M, Theunissen TW, Yu L, Choudhary JS, Hajkova P, et al. Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 2010;24:2772–7.
pubmed: 21159818 pmcid: 3003195 doi: 10.1101/gad.606110
Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.
pubmed: 21386835 doi: 10.1038/nm.2304
Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47–76.
pubmed: 27193450 doi: 10.1146/annurev-pathol-012615-044438
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34.
pubmed: 28985214 doi: 10.1038/nm.4409
Leung TH, Tang HW, Siu MK, Chan DW, Chan KK, Cheung AN, et al. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness. J Pathol. 2018;244:151–63.
pubmed: 28944962 doi: 10.1002/path.4991
Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, et al. Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma. Cancer Cell. 2017;32:411–26 e411.
pubmed: 28966034 pmcid: 5929990 doi: 10.1016/j.ccell.2017.08.018
Gulla A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018;32:996–1002.
pubmed: 29158558 doi: 10.1038/leu.2017.334

Auteurs

Jie Gao (J)

Tianjin Key Laboratory of Inflammatory Biology, The province and ministry co-sponsored collaborative innovation center for medical epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Ruiqiong Liu (R)

The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Dandan Feng (D)

Tianjin Key Laboratory of Inflammatory Biology, The province and ministry co-sponsored collaborative innovation center for medical epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Wei Huang (W)

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Advanced Innovation Center for Human Brain Protection, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Miaomiao Huo (M)

Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jingyao Zhang (J)

Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Shuai Leng (S)

Tianjin Key Laboratory of Inflammatory Biology, The province and ministry co-sponsored collaborative innovation center for medical epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Yang Yang (Y)

Tianjin Key Laboratory of Inflammatory Biology, The province and ministry co-sponsored collaborative innovation center for medical epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Tianshu Yang (T)

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Advanced Innovation Center for Human Brain Protection, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Xin Yin (X)

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Advanced Innovation Center for Human Brain Protection, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Xu Teng (X)

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Advanced Innovation Center for Human Brain Protection, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Hefen Yu (H)

Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Advanced Innovation Center for Human Brain Protection, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Baowen Yuan (B)

Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Yan Wang (Y)

Tianjin Key Laboratory of Inflammatory Biology, The province and ministry co-sponsored collaborative innovation center for medical epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. yanwang@tmu.edu.cn.
Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. yanwang@tmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH